CoChat

Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)

Open access
Wehn, Paul M., Rizzi, James P., Dixon, Darryl D., Grina, Jonas A., Schlachter, Stephen T., Wang, Bin, Xu, Rui, Yang, Hanbiao, Du, Xinlin, Han, Guangzhou, Wang, Keshi, Cao, Zhaodan, Cheng, Tzuling, Czerwinski, Robert M., Goggin, Barry S., Huang, Heli, Halfmann, Megan M., Maddie, Melissa A., Morton, Emily L., Olive, Sarah R., Tan, Huiling, Xie, Shanhai, Wong, Tai, Josey, John A., Wallace, Eli M. · 2018 · Journal of Medicinal Chemistry
Cited by 117

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

HIF-2α, a member of the HIF family of transcription factors, is a key oncogenic driver in cancers such as clear cell renal cell carcinoma (ccRCC). A signature feature of these cancers is the overaccumulation of HIF-2α protein, often by inactivation of the E3 ligase VHL (von Hippel–Lindau). Herein we disclose our structure based drug design (SBDD) approach that culminated in the identification of PT2385, the first HIF-2α antagonist to enter clinical trials. Highlights include the use of a putative n → π* Ar interaction to guide early analog design, the conformational restriction of an essential hydroxyl moiety, and the remarkable impact of fluorination near the hydroxyl group. Evaluation of select compounds from two structural classes in a sequence of PK/PD, efficacy, PK, and metabolite profiling identified 10i (PT2385, luciferase EC 50 = 27 nM) as the clinical candidate. Finally, a retrospective crystallographic analysis describes the structural perturbations necessary for efficient antagonism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.8b01196

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 117

Metadata

Authors
Wehn, P. M., Rizzi, J. P., Dixon, D. D., Grina, J. A., Schlachter, S. T., Wang, B., Xu, R., Yang, H., Du, X., Han, G., Wang, K., Cao, Z., Cheng, T., Czerwinski, R. M., Goggin, B. S., Huang, H., Halfmann, M. M., Maddie, M. A., Morton, E. L., Olive, S. R., Tan, H., Xie, S., Wong, T., Josey, J. A., & Wallace, E. M.
Venue
Journal of Medicinal Chemistry
Published
2018-10-05
Volume
61
Issue
21
Pages
9691-9721
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2895634053
Cited by
117
References
15
FWCI
2.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). https://app.cochat.ai/papers/10.1021/acs.jmedchem.8b01196
The paper
Wehn, P. M., Rizzi, J. P., Dixon, D. D., Grina, J. A., Schlachter, S. T., Wang, B., Xu, R., Yang, H., Du, X., Han, G., Wang, K., Cao, Z., Cheng, T., Czerwinski, R. M., Goggin, B. S., Huang, H., Halfmann, M. M., Maddie, M. A., Morton, E. L., . . . Wallace, E. M. (2018). Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.8b01196

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.